NEW YORK (GenomeWeb) – Exosome Diagnostics announced today that it has partnered with Amgen to develop a liquid biopsy test.
Under the terms of the deal, the companies will use Exosome's technology to identify a potential liquid biopsy diagnostic that may be used in Amgen's drug development processes. Additional terms of the arrangement were not disclosed.
The deal is the latest big pharma alliance for Exosome and follows a June agreement under which the company is developing an exosomal RNA sequencing platform for biomarker discovery with Takeda Pharmaceuticals.